ADMA Biologics to Announce Financial Results
ADMA Biologics, Inc. is preparing to unveil its financial performance for the first quarter of 2025. This exciting announcement will take place on May 7, 2025, following the closure of the U.S. financial markets. As a notable player in the biopharmaceutical industry, ADMA remains dedicated to delivering critical specialty biologics that cater to patients with immunodeficiencies.
Live Conference Call Announcement
To discuss these important financial results, the management team at ADMA will host a live conference call on the same day at 4:30 p.m. ET. This offers an invaluable opportunity for shareholders and interested participants to gain insights into the company’s performance, future direction, and strategic plans moving forward.
How to Access the Conference Call
For seamless access to the conference call, participants are encouraged to register in advance. Preparing ahead of time will ensure you receive the necessary dial-in numbers and a unique PIN for the call. It is wise to join the call approximately 10 minutes before it starts, allowing you to settle in and be ready for the important updates. For those who prefer to listen rather than actively participate, a live audio webcast will be available as well.
ADMA’s Commitment to Biopharmaceutical Development
ADMA Biologics is recognized as an end-to-end commercial biopharmaceutical company based in the U.S. Its core mission is to manufacture, market, and develop unique specialty biologics aimed at treating patients with immune deficiencies and certain infectious diseases. The company proudly markets three FDA-approved plasma-derived biologics, including ASCENIV™, BIVIGAM®, and NABI-HB®, all designed to provide essential support to patients at risk of infection.
Innovative Developments at ADMA
In addition to its approved products, ADMA is also in the advanced stages of developing SG-001, a promising pre-clinical hyperimmune globulin. This innovative product focuses on targeting the bacterial strain S. pneumonia, which poses serious health threats to individuals with compromised immune systems. With a strong focus on research and development, ADMA continuously seeks to expand its product lineup to meet emerging medical needs.
Manufacturing Excellence
Manufacturing is at the heart of ADMA’s operations, as the company runs an FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. This facility is crucial for the production of their immune globulin products and various pipeline candidates. Moreover, through its subsidiary, ADMA BioCenters, the company also acts as an FDA-approved source plasma collector, ensuring a sustainable supply of high-quality blood plasma for its products.
Mission and Values
ADMA’s commitment is to manufacture and develop specialty plasma-derived human immune globulins specifically targeted at niche patient populations. These efforts are essential for the treatment and prevention of diverse infectious diseases, especially for individuals who are immune compromised due to various medical conditions. The company’s extensive portfolio of U.S. and foreign patents reflects its dedication to innovation in the biopharmaceutical space.
Investor Relations and Contact Information
For those interested in learning more about ADMA Biologics or wishing to engage with the company, investor relations inquiries can be directed to Argot Partners. They can be reached at 212-600-1902 or via email. Maintaining open lines of communication with investors is a priority for ADMA, ensuring that all stakeholders are kept informed.
Frequently Asked Questions
When will ADMA Biologics report its financial results?
ADMA Biologics will report its first quarter 2025 financial results on May 7, 2025.
What time is the conference call scheduled?
The conference call is set to begin at 4:30 p.m. ET on the same day the financial results are announced.
How can I participate in the conference call?
Participants must register in advance to receive the dial-in numbers and a unique PIN for the conference call.
What are some of ADMA's key products?
ADMA's key products include ASCENIV™, BIVIGAM®, and NABI-HB® which are FDA-approved for treating immune deficiencies.
What is the mission of ADMA Biologics?
ADMA Biologics aims to manufacture and develop specialty plasma-derived immune globulins to support patients with immune deficiencies and those at risk for infectious diseases.
